207 related articles for article (PubMed ID: 28319682)
1. N-Substituted 5-amino-1-hydroxymethyl-cyclopentanetriols: A new family of activity promotors for a G
Schalli M; Tysoe C; Fischer R; Pabst BM; Thonhofer M; Paschke E; Rappitsch T; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Carbohydr Res; 2017 Apr; 443-444():15-22. PubMed ID: 28319682
[TBL] [Abstract][Full Text] [Related]
2. A new type of pharmacological chaperone for G
Schalli M; Weber P; Tysoe C; Pabst BM; Thonhofer M; Paschke E; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2017 Aug; 27(15):3431-3435. PubMed ID: 28600215
[TBL] [Abstract][Full Text] [Related]
3. Tuning glycosidase inhibition through aglycone interactions: pharmacological chaperones for Fabry disease and GM1 gangliosidosis.
Aguilar-Moncayo M; Takai T; Higaki K; Mena-Barragán T; Hirano Y; Yura K; Li L; Yu Y; Ninomiya H; García-Moreno MI; Ishii S; Sakakibara Y; Ohno K; Nanba E; Ortiz Mellet C; García Fernández JM; Suzuki Y
Chem Commun (Camb); 2012 Jul; 48(52):6514-6. PubMed ID: 22618082
[TBL] [Abstract][Full Text] [Related]
4. Synthesis of C-5a-chain extended derivatives of 4-epi-isofagomine: Powerful β-galactosidase inhibitors and low concentration activators of GM1-gangliosidosis-related human lysosomal β-galactosidase.
Thonhofer M; Weber P; Santana AG; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Bioorg Med Chem Lett; 2016 Mar; 26(5):1438-42. PubMed ID: 26838810
[TBL] [Abstract][Full Text] [Related]
5. (5aR)-5a-C-Pentyl-4-epi-isofagomine: A powerful inhibitor of lysosomal β-galactosidase and a remarkable chaperone for mutations associated with GM1-gangliosidosis and Morquio disease type B.
Front S; Biela-Banaś A; Burda P; Ballhausen D; Higaki K; Caciotti A; Morrone A; Charollais-Thoenig J; Gallienne E; Demotz S; Martin OR
Eur J Med Chem; 2017 Jan; 126():160-170. PubMed ID: 27750150
[TBL] [Abstract][Full Text] [Related]
6. Potent GH20 N-Acetyl-β-d-hexosaminidase Inhibitors: N-Substituted 3-acetamido-4-amino-5-hydroxymethyl-cyclopentanediols.
Weber P; Nasseri SA; Pabst BM; Torvisco A; Müller P; Paschke E; Tschernutter M; Windischhofer W; Withers SG; Wrodnigg TM; Stütz AE
Molecules; 2018 Mar; 23(3):. PubMed ID: 29558439
[TBL] [Abstract][Full Text] [Related]
7. 4-epi-Isofagomine derivatives as pharmacological chaperones for the treatment of lysosomal diseases linked to β-galactosidase mutations: Improved synthesis and biological investigations.
Front S; Almeida S; Zoete V; Charollais-Thoenig J; Gallienne E; Marmy C; Pilloud V; Marti R; Wood T; Martin OR; Demotz S
Bioorg Med Chem; 2018 Nov; 26(20):5462-5469. PubMed ID: 30270003
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Insights into the Chaperoning of Human Lysosomal-Galactosidase Activity: Highly Functionalized Aminocyclopentanes and
Weber P; Thonhofer M; Averill S; Davies GJ; Santana AG; Müller P; Nasseri SA; Offen WA; Pabst BM; Paschke E; Schalli M; Torvisco A; Tschernutter M; Tysoe C; Windischhofer W; Withers SG; Wolfsgruber A; Wrodnigg TM; Stütz AE
Molecules; 2020 Sep; 25(17):. PubMed ID: 32899288
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable β-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal β-galactosidase mutant R201C.
Thonhofer M; Weber P; Gonzalez Santana A; Tysoe C; Fischer R; Pabst BM; Paschke E; Schalli M; Stütz AE; Tschernutter M; Windischhofer W; Withers SG
Carbohydr Res; 2016 Jun; 429():71-80. PubMed ID: 27063389
[TBL] [Abstract][Full Text] [Related]
10. DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts.
Fantur K; Hofer D; Schitter G; Steiner AJ; Pabst BM; Wrodnigg TM; Stütz AE; Paschke E
Mol Genet Metab; 2010 Jul; 100(3):262-8. PubMed ID: 20409738
[TBL] [Abstract][Full Text] [Related]
11. Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.
Zhang S; Bagshaw R; Hilson W; Oho Y; Hinek A; Clarke JT; Callahan JW
Biochem J; 2000 Jun; 348 Pt 3(Pt 3):621-32. PubMed ID: 10839995
[TBL] [Abstract][Full Text] [Related]
12. Structural basis of pharmacological chaperoning for human β-galactosidase.
Suzuki H; Ohto U; Higaki K; Mena-Barragán T; Aguilar-Moncayo M; Ortiz Mellet C; Nanba E; Garcia Fernandez JM; Suzuki Y; Shimizu T
J Biol Chem; 2014 May; 289(21):14560-8. PubMed ID: 24737316
[TBL] [Abstract][Full Text] [Related]
13. Molecular consequences of the pathogenic mutation in feline GM1 gangliosidosis.
Martin DR; Rigat BA; Foureman P; Varadarajan GS; Hwang M; Krum BK; Smith BF; Callahan JW; Mahuran DJ; Baker HJ
Mol Genet Metab; 2008 Jun; 94(2):212-21. PubMed ID: 18353697
[TBL] [Abstract][Full Text] [Related]
14. 5-Fluoro derivatives of 4-epi-isofagomine as D-galactosidase inhibitors and potential pharmacological chaperones for GM1-gangliosidosis as well as Fabry's disease.
Thonhofer M; Gonzalez Santana A; Fischer R; Torvisco Gomez A; Saf R; Schalli M; Stütz AE; Withers SG
Carbohydr Res; 2016 Feb; 420():6-12. PubMed ID: 26717544
[TBL] [Abstract][Full Text] [Related]
15. The potential action of galactose as a "chemical chaperone": increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient.
Caciotti A; Donati MA; d'Azzo A; Salvioli R; Guerrini R; Zammarchi E; Morrone A
Eur J Paediatr Neurol; 2009 Mar; 13(2):160-4. PubMed ID: 18571950
[TBL] [Abstract][Full Text] [Related]
16. Fluorous iminoalditols act as effective pharmacological chaperones against gene products from GLB₁ alleles causing GM1-gangliosidosis and Morquio B disease.
Fantur KM; Wrodnigg TM; Stütz AE; Pabst BM; Paschke E
J Inherit Metab Dis; 2012 May; 35(3):495-503. PubMed ID: 22033734
[TBL] [Abstract][Full Text] [Related]
17. Chaperone therapy update: Fabry disease, GM1-gangliosidosis and Gaucher disease.
Suzuki Y
Brain Dev; 2013 Jun; 35(6):515-23. PubMed ID: 23290321
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
19. Normal serum beta-galactosidase in juvenile GM1 gangliosidosis.
Ishii N; Oshima A; Sakuraba H; Fukuyama Y; Suzuki Y
Pediatr Neurol; 1994 Jun; 10(4):317-9. PubMed ID: 8068159
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological Chaperones for β-Galactosidase Related to G
Stütz AE; Thonhofer M; Weber P; Wolfsgruber A; Wrodnigg TM
Chem Rec; 2021 Nov; 21(11):2980-2989. PubMed ID: 34816592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
